Scientists have unveiled the most comprehensive map of the brain’s basal ganglia, profiling 25.5 million individual cells from humans, macaques and marmosets. The effort, part of the U.S. National Institutes of Health’s BRAIN Initiative Cell Atlas Network (BICAN), aims to provide a reference framework for studying motor, cognitive and mood disorders that involve this deep‑brain region.
Scale and scope of the atlas
The new atlas combines data from six human donors, three rhesus and cynomolgus macaques and two marmosets, amounting to roughly 21 million human cells, 3 million primate cells and 1.5 million marmoset cells. Researchers also incorporated previously published mouse brain maps to broaden comparative analyses. Across the three primate species, 61 distinct cell types were found to be conserved for about 76 million years of evolution.
By integrating gene‑expression profiles, DNA‑modification patterns, electrophysiological recordings and three‑dimensional nuclear architecture, the team generated a multi‑modal description of each cell type. Michael Hawrylycz of the Allen Institute for Brain Science described the resulting dataset as a “scaffold” that can support future mapping of the entire mammalian brain.
Molecular zoning of the striatum
One of the studies focused on the striatum, the largest structure within the basal ganglia. Analyzing 1.1 million cells from 19 deceased human donors, researchers identified six molecularly distinct zones, each with unique neuronal and glial populations. Although these zones appear indistinguishable under a microscope, transcriptional signatures differ strongly and remain consistent across individuals.
Evan Macosko of the Broad Institute noted that the zones’ gene‑expression patterns converge with age, especially in regions vulnerable to Huntington’s and Parkinson’s disease. This age‑related homogenization may provide clues to why neurodegeneration intensifies later in life.
Implications for disease research
A separate analysis examined nearly four million cells from the striatum and prefrontal cortex of 178 adult donors ranging from 27 to over 90 years old. The work highlighted substantial inter‑individual variability, particularly among glial cells, underscoring the importance of accounting for personal differences in cell‑type composition when investigating disease mechanisms.
The atlas also includes understudied neuronal subtypes and offers insights into how specific cells change with age. Such detailed reference maps are expected to accelerate the identification of cellular contributors to neurodegenerative and psychiatric conditions, from Parkinson’s and Huntington’s disease to schizophrenia, bipolar disorder and addiction.
“It’s a massive dictionary that we needed in the field,” said Ana Muñoz‑Manchado of the University of Cádiz, who studies basal ganglia involvement in neurodegeneration. The project represents a collaboration among hundreds of scientists across nine countries and is documented in a collection of 26 papers published in Cell, Cell Reports, Cell Reports Methods, Cell Systems, Cell Genomics and Neuron.
As the BICAN initiative continues, the basal ganglia atlas will serve as a reference point for future studies aiming to translate cellular insights into therapeutic strategies for a range of brain disorders.
Mitchell Landsberg is a Senior Technology Correspondent at News Raise. He covers consumer electronics, artificial intelligence, software developments, and digital privacy trends.




